CD8A and neoplasm: The second nomogram was built to predict probability of PFS at 4-, 8- and 12-months for aNSCLC patients treated with anti-PD-1 antibodies based on hepatic metastases, tumor size, and baseline AC of CD3 + , CD4 + , CD8+ and B cells (Fig. 6B).